Ypsomed Holding AGXSWX:YPSN +1.91%91 ROE % is 21.30% as of Mar. 2026, which is 59% above its 10-year median of 13.39. GuruFocus rates XSWX:YPSN with a GF Score™ of 91/100 and a GF Value™ of CHF397.48 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 799 Medical Devices & Instruments companies, Ypsomed Holding AG ranks better than 95.74% on this metric.
The historical rank and industry rank for Ypsomed Holding AG's ROE % or its related term are showing as below:
XSWX:YPSN'
s ROE % Range Over the Past 10 Years
Min: 1.5 Med: 13.39 Max: 31.09
Current: 29.79
During the past 13 years, Ypsomed Holding AG's highest ROE % was 31.09%. The lowest was 1.50%. And the median was 13.39%.
XSWX:YPSN's ROE % is ranked better than 95.74% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 2.42
vs XSWX:YPSN: 29.79
Ypsomed Holding AG (XSWX:YPSN) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Ypsomed Holding AG ROE % Related Terms
Ypsomed Holding AG ROE % Historical Data
* Premium members only.
The historical data trend for Ypsomed Holding AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Ypsomed Holding AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ypsomed Holding AG ROE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ypsomed Holding AG's ROE % distribution charts can be found below:
* The bar in red indicates where Ypsomed Holding AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Ypsomed Holding AG (XSWX:YPSN) has a ROE % of 21.30% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ypsomed Holding AG and its competitors. This is 59% above median its historical median of 13.39. Over the past decade, Ypsomed Holding AG's ROE % has ranged from 1.50 to 31.09. According to the industry distribution chart, Ypsomed Holding AG ranks #34 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is Ypsomed Holding AG's ROE % too high?
Ypsomed Holding AG's current ROE % of 21.30% is 59% above median its 10-year median of 13.39. Over the past 10 years, this metric has ranged from a low of 1.50 to a high of 31.09. The Medical Devices & Instruments industry median ROE % is 2.42. Ypsomed Holding AG's value of 21.30% is 780.2% above this industry median. Based on the distribution chart, Ypsomed Holding AG ranks #34 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Ypsomed Holding AG has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ypsomed Holding AG's ROE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ypsomed Holding AG ranks #34 out of 799 companies for ROE %. This places Ypsomed Holding AG in the top 4% of its industry — outperforming the majority of peers. The industry median ROE % is 2.42. Ypsomed Holding AG's value of 21.30% is 780.2% above this benchmark. Historically, Ypsomed Holding AG's own ROE % has ranged from 1.50 to 31.09 over the past decade. While the company's 10-year median is 13.39 vs. the industry median of 2.42, Ypsomed Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Devices & Instruments company?
The median ROE % among Medical Devices & Instruments companies is 2.42, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ypsomed Holding AG's current ROE % of 21.30% is 780.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Ypsomed Holding AG and its competitors. For the Medical Devices & Instruments industry, the median ROE % is 2.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ypsomed Holding AG's current ROE % is 21.30%, which is 59% above median its own 10-year median of 13.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ypsomed Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Ypsomed Holding AG (XSWX:YPSN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF397.48, compared to a current price of CHF353.00 — trading 11.2% below its estimated fair value. The current ROE % is 21.30%, which is 59% above median its 10-year median of 13.39 and 780.2% above the Medical Devices & Instruments industry median of 2.42. Ypsomed Holding AG's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Ypsomed Holding AG (XSWX:YPSN), the current ROE % is 21.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ypsomed Holding AG (XSWX:YPSN) Overvalued in 2026?
Based on GuruFocus' analysis, Ypsomed Holding AG stock appears to be undervalued.
The current stock price of CHF353.00 is trading 11.2% below its estimated GF Value™ of CHF397.48.
GuruFocus considers Ypsomed Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:YPSN:
ROE %: 21.30% (59% above median its 10-year median of 13.39)
GF Value™: CHF397.48 vs. price of CHF353.00 (11.2% below fair value)
Industry Position: 780.2% above the Medical Devices & Instruments median (#34 of 799)
No single metric tells the full story. See the XSWX:YPSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ypsomed Holding AG is a Swiss company that develops and manufactures injection and infusion systems that allow patients to self-administer medication. Specifically, the company focuses on ensuring the ease of diabetes and insulin injection. The company offers various products such as pen needles with a click-on function. The company operates under two reportable segments: Ypsomed Delivery Systems and Ypsomed Diabetes Care.
91GF Score
Get the complete analysis for XSWX:YPSN
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:YPSN has been successfully added to your 
